On May 13, 2019, Milestone Pharmaceuticals Inc. announced the closing of its previously announced initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share. Milestone Pharmaceuticals Inc., a Montreal-based company, is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications.
Osler, Hoskin & Harcourt LLP advised Milestone Pharmaceuticals Inc. with a team led by Nathalie Beauregard (Corporate) and consisting of Jeremy Brisset, Fancois Paradis, and Daniel Stysis (Corporate).
Key Contact
Partner, Emerging and High Growth Companies, Montréal
Team
Associate, Corporate, Montréal
Partner, Corporate, Montréal
Partner, Corporate, Montréal
